GVS advice avatrombopag (Doptelet®) for the treatment of thrombocytopenia

Zorginstituut Nederland has completed its assessment whether avatrombopag (Doptelet®) is interchangeable with a product that is included in the Medicine Reimbursement System (GVS). Avatrombopag (Doptelet®) is indicated for the treatment of thrombocytopenia. The Zorginstituut recommends to include avatrombopag (Doptelet®) with eltrombopag (Revolade®) in the newly formed cluster on List 1A of the GVS. 

Registered indication

Avatrombopag (Doptelet®) is indicated for the treatment of: 

  • primary chronic immune thrombocytopenia (ITP) in adult patients resistant to other treatments (e.g. corticosteroids, immunoglobulins); 
  • severe thrombocytopenia in adult patients with chronic liver disease scheduled for an invasive procedure.

Avatrombopag is available as a film-coated tablet.

Review of interchangeability

On the basis of the criteria for interchangeability, it can be concluded that avatrombopag is interchangeable with eltrombopag (Revolade®).

Zorginstituut's advice

The Zorginstituut advises the Minister to include avatrombopag (Doptelet®) with eltrombopag (Revolade®) in the newly formed cluster on List 1A of the GVS. 20 mg/day can be applied as the standard dose for avatrombopag. The standard dose for eltrombopag can be set at 50 mg per day.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.